drugset / Trial / NCT07084961

A Pharmacodynamic Study of TS-172 in Healthy Adult Male Subjects

NCT07084961

Phase 1 Completed 16 enrolled Taisho Pharmaceutical Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

An open-label, single-center, crossover study to evaluate the impact of administration timing of TS-172 on the pharmacodynamics in healthy adult male subjects.

Timeline

Start
2025-08-05
Primary completion
2025-09-11
Completion
2025-09-16

Drugs

EvaluationDrugModalityDoseRoute
Subject TS-172 Unknown 20 mg Oral

Indications

No indication recorded.